Bristol-Myers Squibb to Acquire Mirati Therapeutics for $5.8B to Boost Oncology Range

Bristol-Myers Squibb plans to acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion. This move will diversify Bristol-Myers Squibb's oncology business and add innovative drugs that can help offset the expected revenue loss from future patent expirations.

According to a Reuters report, Mirati Therapeutics brings a portfolio of drugs targeting certain cancers' genetic drivers. Notably, their lung cancer drug, Krazati, gained approval from the U.S. Food and Drug Administration in December.

This breakthrough drug, combined with a second compound called MRTX1719, which holds promise for treating specific types of lung cancer, caught the attention of Bristol-Myers Squibb.

Strategic Move Amidst Generic Competition

Under the terms of the agreement, Bristol-Myers Squibb will acquire Mirati for $58 per share in cash, totaling approximately $4.8 billion, according to CNBC. Furthermore, Mirati shareholders will also receive a non-tradeable contingent value right, potentially worth $12 per share in cash, bringing an additional $1 billion of value opportunity to the deal. Bristol-Myers Squibb will utilize cash and debt to finance this transaction.

This acquisition is critical for Bristol-Myers Squibb as it faces declining demand for two of its top drugs, Revlimid and Eliquis, due to generic competition. By acquiring Mirati Therapeutics, Bristol-Myers Squibb aims to strengthen its foothold in the oncology market and tap into the potential of innovative cancer treatments.

"We think this really helps strategically complement our oncology portfolio but also, from a financial standpoint, it helps out commercially in the back half of the decade," said Adam Lenkowsky, Bristol's Chief Commercialization Officer.

Mirati's shares, reaching a 52-week high of $101.3 per share, now trade at $60.2, making the acquisition economically advantageous for Bristol-Myers Squibb. The company believes it has secured an attractive deal with significant potential for future growth.

Impact on Bristol-Myers Squibb's Financial Outlook

Bristol-Myers Squibb expects the acquisition to be dilutive to its non-GAAP earnings per share by approximately 35 cents in the first 12 months after the transaction is finalized. However, the long-term benefits of expanding its oncology portfolio justify this temporary impact.

In April, Bristol-Myers Squibb announced the upcoming departure of CEO Giovanni Caforio, whom Boerner will succeed in November. This leadership transition, combined with the company's previous acquisition of Turning Point Therapeutics for $4.1 billion, demonstrates Bristol-Myers Squibb's commitment to enhancing its range of cancer-fighting medications.

With the acquisition of Mirati Therapeutics, Bristol-Myers Squibb is poised to strengthen its position in the global oncology market. By leveraging Mirati's advanced cancer drugs and addressing the challenges posed by generic competition, Bristol-Myers Squibb aims to continue improving patients' lives and pushing the boundaries of cancer treatment.

Embracing the Power of Personalized Medicine

Integrating Mirati's groundbreaking drugs into Bristol-Myers Squibb's existing pipeline emphasizes the company's commitment to developing cutting-edge therapies. This strategic move bolsters their portfolio and positions them at the forefront of the fight against cancer.

Mirati's drugs, designed to target the genetic drivers of specific cancers, align with Bristol-Myers Squibb's vision for advancing personalized medicine. The company aims to revolutionize how cancer is diagnosed and treated by tailoring treatments to individual patients.

Photo: Alexander Grey/Unsplash